Spots Global Cancer Trial Database for Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
Official Title: A Phase I, Open-Label, Two-Stage Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral AKT Inhibitor GSK2110183 in Subjects With Any Hematologic Malignancy
Study ID: NCT00881946
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Prince of Wales Hospital, Sydney, New South Wales, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
Princess Margaret Hospital, Toronto, Ontario, Canada
Seoul National University Hospital, Seoul, , Korea, Republic of
Contact Details
Name: S. Jamie Freedman, MD, PhD
Affiliation:
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
